Assertio (ASRT) Projected to Post Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT) is expected to release its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect Assertio to post earnings of ($0.08) per share and revenue of $27.02 million for the quarter. Assertio has set its FY 2025 guidance at EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Assertio (NASDAQ:ASRT) last posted its earnings results on Monday, August 11th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Assertio had a negative net margin of 36.97% and a negative return on equity of 38.19%. The firm had revenue of $29.22 million during the quarter, compared to analyst estimates of $27.86 million. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Assertio Stock Performance

Assertio stock opened at $0.74 on Monday. The firm has a 50 day simple moving average of $0.84 and a 200-day simple moving average of $0.74. The stock has a market cap of $71.64 million, a price-to-earnings ratio of -1.65 and a beta of 0.28. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.59 and a quick ratio of 1.34. Assertio has a 1-year low of $0.51 and a 1-year high of $1.08.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ASRT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assertio in a research report on Wednesday, October 8th. Zacks Research upgraded Assertio from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Finally, HC Wainwright reduced their price objective on shares of Assertio from $3.50 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $2.38.

Hedge Funds Weigh In On Assertio

A hedge fund recently raised its stake in Assertio stock. Nantahala Capital Management LLC boosted its position in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 4.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,810,073 shares of the company’s stock after acquiring an additional 370,311 shares during the quarter. Nantahala Capital Management LLC owned 9.15% of Assertio worth $5,649,000 at the end of the most recent quarter. Institutional investors own 48.96% of the company’s stock.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.